In a 40‑year‑old woman using a Mirena levonorgestrel intrauterine device, what does an elevated follicle‑stimulating hormone (~60–68 IU/L), elevated luteinizing hormone (31.7 IU/L), low estradiol (34 pg/mL) and low progesterone (0.1 ng/mL) indicate and how should it be managed?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Premature Ovarian Insufficiency Diagnosis

This 40-year-old woman meets diagnostic criteria for premature ovarian insufficiency (POI) and requires immediate hormone replacement therapy, genetic testing, and autoimmune screening. 1

Diagnostic Interpretation

The laboratory findings definitively indicate POI:

  • FSH consistently >40 IU/L (58.3 and 67.8 IU/L) with elevated LH (31.7 IU/L) and low estradiol (34.1 pg/mL) establish the diagnosis of POI, defined as loss of ovarian activity before age 40 with menstrual disturbance, raised gonadotropins, and low estradiol 1

  • The Mirena IUD does not interfere with this diagnosis. The levonorgestrel-releasing intrauterine system primarily exerts local endometrial effects and does not suppress ovarian function or FSH levels—studies show that 78.5% of long-term Mirena users maintain ovulatory cycles with normal gonadotropin patterns 2, 3

  • The low progesterone (0.1 ng/mL) reflects absent ovulation, consistent with ovarian failure rather than any IUD effect 2

Immediate Management Steps

Hormone Replacement Therapy

Initiate systemic estrogen-progestin hormone therapy immediately to prevent long-term health consequences including bone loss, cardiovascular disease, and neurological dysfunction 1. The Mirena's local progestin effect does not provide systemic hormone replacement needed for POI.

Essential Screening Tests

Perform fragile-X premutation testing before discussing implications with the patient, as this is indicated in all women with POI 1

Screen for 21-hydroxylase antibodies (21OH-Ab) or adrenocortical antibodies (ACA) to identify autoimmune POI 1:

  • If positive, refer immediately to endocrinology for adrenal function testing to rule out Addison's disease, which can be life-threatening if undiagnosed 1

Autosomal genetic testing is not routinely indicated unless specific syndromic features are present (e.g., blepharophimosis-ptosis-epicanthus inversus syndrome) 1

Critical Clinical Considerations

Contraception Decision

  • The Mirena can remain in place if contraception is desired, as spontaneous ovulation and pregnancy remain possible (though rare) in POI 1
  • Discuss fertility preservation options and the unpredictable nature of ovarian function in POI 1

Long-term Health Monitoring

Address consequences across multiple domains 1:

  • Bone health: Baseline DEXA scan and ongoing monitoring
  • Cardiovascular risk: Aggressive risk factor modification
  • Psychosexual and psychological function: Counseling and support resources
  • Neurological function: Long-term follow-up

Common Pitfall

Do not attribute the elevated FSH to perimenopausal transition or dismiss it as "early menopause"—POI at age 40 is a distinct clinical syndrome affecting 1% of women and requires comprehensive evaluation and management beyond simple hormone replacement 1

Related Questions

How to interpret hormone levels during perimenopause in women using a Mirena (levonorgestrel) intrauterine device (IUD)?
Does the levonorgestrel‑releasing intrauterine system (Mirena) increase serum prolactin in a reproductive‑aged woman without other endocrine disorders?
Can hormone testing be done in patients with a Mirena (levonorgestrel) Intrauterine Device (IUD)?
In a 34‑year‑old woman with follicle‑stimulating hormone 5.1 U/L, luteinizing hormone 7.5 U/L, estradiol 130 pmol/L and progesterone <1 nmol/L, what does this hormone profile indicate about her menstrual phase and ovulation status?
How should the estradiol 208 pg/mL, progesterone 1.2 ng/mL, follicle‑stimulating hormone 8.8 IU/L, and luteinizing hormone 3.5 IU/L results be interpreted in a 48‑year‑old woman?
What is the recommended dosing order for acetylcysteine (Mucomyst) for mucolytic therapy in adults and children, and for acetaminophen overdose?
What are the pathophysiology and treatment options for subglottic stenosis?
For a 6‑year‑old child weighing 21 kg with fever, how many milliliters of intravenous acetaminophen (paracetamol) 300 mg/2 mL should be administered every 4 hours?
What alternative anti‑angiogenic medication comparable to bevacizumab can be used in a patient with a history of gastrointestinal perforation?
How should a patient with a persistent moist cough after recent treatment for pneumonia and pneumothorax be evaluated and managed?
How should I manage a 37-year-old male with an asthma exacerbation presenting with shortness of breath, continuous cough for 1.5 weeks with vomiting, using albuterol inhaler three times daily without a maintenance inhaler, spirometry values of 325 mL, 350 mL, and 400 mL, clear lung auscultation, and oxygen saturation of 98%?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.